India should examine trade margins across medicines, medical devices and consumables using a common, scientifically credible method - not a...

India's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driv...

Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...

For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...

The Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...

Zydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...

An expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...

The Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...

Hospital stocks rose up to 5% after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing med...

The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...

Karnataka conducted inspections revealing significant price disparities between hospital procurement and patient billing for cancer drugs a...

The Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the...

Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, d...

Biocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 cr...

Active Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development...

Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...

In a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...